Date published: 2026-4-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

NCOAT Inhibitors

The identified chemicals, acting as indirect inhibitors of NCOAT, exert their effects through modulation of specific signaling pathways. Suramin, Resveratrol, Imatinib, Nifedipine, Wortmannin, AG-490, Rapamycin, PD98059, LY294002, SB203580, SP600125, and U0126 impact diverse cellular processes by influencing pathways such as purinergic signaling, sirtuin regulation, Bcr-Abl signaling, L-type calcium channels, PI3K-Akt, JAK-STAT, mTOR, MAPK/ERK, and JNK. The indirect modulation of NCOAT by these chemicals may involve alterations in phosphorylation status and enzymatic activity, contributing to the regulation of cellular functions influenced by NCOAT and the associated signaling cascades. NCOAT inhibitors encompass a range of compounds that, while not directly targeting NCOAT, exert their inhibitory effects through the modulation of specific signaling pathways. These pathways, including purinergic signaling, sirtuin regulation, Bcr-Abl signaling, L-type calcium channels, PI3K-Akt, JAK-STAT, mTOR, MAPK/ERK, and JNK, play crucial roles in cellular processes influenced by NCOAT. The identified chemicals, such as Suramin, Resveratrol, Imatinib, and others, can indirectly impact NCOAT activity, altering its phosphorylation status and enzymatic function. This class of inhibitors serves as valuable tools for exploring the intricate regulatory networks governing NCOAT and its involvement in various cellular functions. Understanding the specific pathways affected by these inhibitors contributes to advancing our knowledge of NCOAT-associated signaling and its implications in diverse biological contexts.

Items 11 to 15 of 15 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 is a potential indirect inhibitor of NCOAT through its action on the MAPK/ERK signaling pathway. By inhibiting MEK1/2, PD98059 disrupts the phosphorylation cascade mediated by MAPK/ERK, which may have downstream effects on NCOAT activity. The modulation of MAPK/ERK signaling can indirectly influence NCOAT function and cellular processes regulated by this enzyme and the MAPK/ERK pathway.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a potential indirect inhibitor of NCOAT, acting through the PI3K-Akt signaling pathway. By inhibiting PI3K, LY294002 disrupts the phosphorylation cascade mediated by PI3K, which may have downstream effects on NCOAT activity. The modulation of PI3K-Akt signaling can indirectly influence NCOAT function and cellular processes regulated by this enzyme.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a potential indirect inhibitor of NCOAT through its action on the p38 MAPK signaling pathway. By inhibiting p38 MAPK, SB203580 disrupts the phosphorylation cascade mediated by this pathway, which may have downstream effects on NCOAT activity. The modulation of p38 MAPK signaling can indirectly influence NCOAT function and cellular processes regulated by this enzyme and the p38 MAPK pathway.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a potential indirect inhibitor of NCOAT, acting through the JNK signaling pathway. By inhibiting JNK, SP600125 disrupts the phosphorylation cascade mediated by this pathway, which may have downstream effects on NCOAT activity. The modulation of JNK signaling can indirectly influence NCOAT function and cellular processes regulated by this enzyme and the JNK pathway.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 is a potential indirect inhibitor of NCOAT through its action on the MAPK/ERK signaling pathway. By inhibiting MEK1/2, U0126 disrupts the phosphorylation cascade mediated by MAPK/ERK, which may have downstream effects on NCOAT activity. The modulation of MAPK/ERK signaling can indirectly influence NCOAT function and cellular processes regulated by this enzyme and the MAPK/ERK pathway.